| The orexin antagonist SB-649868 promotes and maintains sleep in men with primary insomnia P Bettica, L Squassante, S Zamuner, G Nucci, H Danker-Hopfe, E Ratti Sleep 35 (8), 1097-1104, 2012 | 94 | 2012 |
| Phase I studies on the safety, tolerability, pharmacokinetics and pharmacodynamics of SB-649868, a novel dual orexin receptor antagonist P Bettica, G Nucci, C Pyke, L Squassante, S Zamuner, E Ratti, R Gomeni, ... Journal of Psychopharmacology 26 (8), 1058-1070, 2012 | 73 | 2012 |
| Results from 2 randomized, double-blind, placebo-controlled studies of the novel NK1 receptor antagonist casopitant in patients with major depressive disorder E Ratti, K Bellew, P Bettica, H Bryson, S Zamuner, G Archer, ... Journal of clinical psychopharmacology 31 (6), 727-733, 2011 | 72 | 2011 |
| Full central neurokinin-1 receptor blockade is required for efficacy in depression: evidence from orvepitant clinical studies E Ratti, P Bettica, R Alexander, G Archer, D Carpenter, G Evoniuk, ... Journal of psychopharmacology 27 (5), 424-434, 2013 | 70 | 2013 |
| Safety, tolerability, efficacy and pharmacodynamics of the selective JAK1 inhibitor GSK2586184 in patients with systemic lupus erythematosus L Kahl, J Patel, M Layton, M Binks, K Hicks, G Leon, E Hachulla, ... Lupus 25 (13), 1420-1430, 2016 | 61 | 2016 |
| Prediction of repeat-dose occupancy from single-dose data: characterisation of the relationship between plasma pharmacokinetics and brain target occupancy S Abanades, J Van Der Aart, JAR Barletta, C Marzano, GE Searle, ... Journal of Cerebral Blood Flow & Metabolism 31 (3), 944-952, 2011 | 61 | 2011 |
| Translational characterization of [11C]GSK931145, a PET ligand for the glycine transporter type 1 RN Gunn, V Murthy, AM Catafau, G Searle, S Bullich, M Slifstein, ... Synapse 65 (12), 1319-1332, 2011 | 52 | 2011 |
| CCL20 neutralization by a monoclonal antibody in healthy subjects selectively inhibits recruitment of CCR6+ cells in an experimental suction blister G Bouma, S Zamuner, K Hicks, A Want, J Oliveira, A Choudhury, S Brett, ... British journal of clinical pharmacology 83 (9), 1976-1990, 2017 | 46 | 2017 |
| Safety, tolerability, pharmacokinetics and pharmacodynamics of an anti-oncostatin M monoclonal antibody in rheumatoid arthritis: results from phase II randomized, placebo … EH Choy, M Bendit, D McAleer, F Liu, M Feeney, S Brett, S Zamuner, ... Arthritis research & therapy 15, 1-10, 2013 | 46 | 2013 |
| Multinomial logistic estimation of Markov-chain models for modeling sleep architecture in primary insomnia patients R Bizzotto, S Zamuner, G De Nicolao, MO Karlsson, R Gomeni Journal of pharmacokinetics and pharmacodynamics 37, 137-155, 2010 | 46 | 2010 |
| Adaptive‐optimal design in PET occupancy studies S Zamuner, VL Di Iorio, J Nyberg, RN Gunn, VJ Cunningham, R Gomeni, ... Clinical Pharmacology & Therapeutics 87 (5), 563-571, 2010 | 38 | 2010 |
| Efficacy, safety, and tolerability of a triple reuptake inhibitor GSK372475 in the treatment of patients with major depressive disorder: two randomized, placebo-and active … S Learned, O Graff, S Roychowdhury, R Moate, KR Krishnan, G Archer, ... Journal of Psychopharmacology 26 (5), 653-662, 2012 | 37 | 2012 |
| In vivo affinity and target engagement in skin and blood in a first‐time‐in‐human study of an anti‐oncostatin M monoclonal antibody J Reid, S Zamuner, K Edwards, SA Rumley, K Nevin, M Feeney, ... British Journal of Clinical Pharmacology 84 (10), 2280-2291, 2018 | 35 | 2018 |
| Efficacy of vestipitant, a neurokinin-1 receptor antagonist, in primary insomnia E Ratti, DJ Carpenter, S Zamuner, S Fernandes, L Squassante, ... Sleep 36 (12), 1823-1830, 2013 | 32 | 2013 |
| Disposition and metabolism of [14C] SB-649868, an orexin 1 and 2 receptor antagonist, in humans C Renzulli, M Nash, M Wright, S Thomas, S Zamuner, M Pellegatti, ... Drug metabolism and disposition 39 (2), 215-227, 2011 | 31 | 2011 |
| A pharmacokinetic PET study of NK1 receptor occupancy S Zamuner, EA Rabiner, SA Fernandes, M Bani, RN Gunn, R Gomeni, ... European journal of nuclear medicine and molecular imaging 39, 226-235, 2012 | 28 | 2012 |
| Central nervous system effects of the interaction between risperidone (single dose) and the 5‐HT6 antagonist SB742457 (repeated doses) in healthy men M Liem‐Moolenaar, M Rad, S Zamuner, AF Cohen, F Lemme, KL Franson, ... British journal of clinical pharmacology 71 (6), 907-916, 2011 | 27 | 2011 |
| Estimate the time varying brain receptor occupancy in PET imaging experiments using non-linear fixed and mixed effect modeling approach S Zamuner, R Gomeni, A Bye Nuclear medicine and biology 29 (1), 115-123, 2002 | 26 | 2002 |
| Evaluation of antidepressant properties of the p38 MAP kinase inhibitor losmapimod (GW856553) in Major Depressive Disorder: Results from two randomised, placebo-controlled … A Inamdar, E Merlo-Pich, M Gee, C Makumi, P Mistry, J Robertson, ... Journal of Psychopharmacology 28 (6), 570-581, 2014 | 21 | 2014 |
| A non-linear mixed effect modelling approach for metabolite correction of the arterial input function in PET studies M Veronese, RN Gunn, S Zamuner, A Bertoldo Neuroimage 66, 611-622, 2013 | 16 | 2013 |
